Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Evaluating Nanomedicines: Obstacles and Advancements.

Magdalena Swierczewska1, Rachael M Crist1, Scott E McNeil2

  • 1Cancer Research Technology Program, Nanotechnology Characterization Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, P.O. Box B, Frederick, MD, 21702, USA.

Methods in Molecular Biology (Clifton, N.J.)
|October 18, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community.

Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology·2025
Same author

Advancements in Nanoparticle Characterization.

Methods in molecular biology (Clifton, N.J.)·2024
Same author

Trends and patterns in cancer nanotechnology research: A survey of NCI's caNanoLab and nanotechnology characterization laboratory.

Advanced drug delivery reviews·2022
Same author

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery.

Pharmaceuticals (Basel, Switzerland)·2022
Same author

A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways.

Annals of the New York Academy of Sciences·2021
Same author

Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.

Molecules (Basel, Switzerland)·2021

Advancements in nanotechnology offer improved cancer treatment through controlled drug delivery. This chapter details updated characterization methods crucial for evaluating nanomedicines during preclinical development.

Area of Science:

  • Nanomedicine
  • Biotechnology
  • Materials Science

Background:

  • Nanotechnology advancements are revolutionizing medical research, particularly in cancer treatment via drug delivery systems.
  • Nanoparticle-based drug delivery offers enhanced control over biodistribution, improving therapeutic efficacy and reducing side effects.
  • Several nanomedicines have successfully transitioned into clinical use over the past two decades.

Purpose of the Study:

  • To discuss the evolving characterization challenges for nanoparticles used in drug delivery.
  • To present updated protocols for evaluating nanomedicines in preclinical development.
  • To highlight advancements and improvements in nanomedicine characterization techniques.

Main Methods:

  • Review of current nanotechnology applications in drug delivery.
Keywords:
Active targetingEfficacyNanomedicineNanoparticlesPassive targetingTherapyToxicity

Related Experiment Videos

  • Analysis of established and emerging characterization protocols for nanomedicines.
  • Case examples of improved characterization methods for preclinical nanomedicine development.

    • Main Results:

    • Characterization methods must adapt to the increasing complexity and clinical translation of nanomedicines.
    • Updated protocols are essential for robust safety and efficacy evaluation of nanomedicines.
    • Specific advancements in nanoparticle characterization address key challenges in nanomedicine development.

    Conclusions:

    • Effective characterization is paramount for the successful clinical translation of nanomedicines.
    • Continuous evolution of characterization techniques is necessary to meet regulatory and developmental demands.
    • This work provides essential guidance for researchers and developers in the field of nanomedicine.